Weight-loss drug linked to lower eye-disease risk in patients with diabetes

The popular diabetes and weight-loss medication tirzepatide may lower the risk of diabetic retinopathy, a leading cause of vision loss, according to Weill Cornell Medicine investigators.

How food shortages reprogram immune system response

When food is scarce, stress hormones direct the immune system to operate in “low power” mode to preserve immune function while conserving energy.

Robotic medical crash cart eases workload for healthcare teams

Researchers have unveiled a robotic crash cart that uses verbal and visual cues to help healthcare teams access the right tools — fast. 

Around Cornell

Task force recommends restraint in use of institutional voice

Cornell leadership will apply principles of institutional restraint to decisions about when and how the university should comment publicly on matters of social and political significance.

Thorsten Joachims named vice provost for AI strategy

Joachims, professor of computer science and information science and director of the Cornell AI initiative, will coordinate AI across research, education and operations.

Discovery illuminates how inflammatory bowel disease promotes colorectal cancer

Research unveiled a chain of immune reactions in the gut driven by a key signaling protein and a surge of white blood cells from the bone marrow.

Americans still see opioid overdose as a crisis

Approximately 88% of adults view opioid overdose deaths as a very serious problem with high agreement across political groups, according to a national survey conducted by Weill Cornell Medicine researchers.

Pre-cancerous states identified in seemingly normal aging tissues

A new single-cell profiling technique has mapped pre-malignant gene mutations and their effects in solid tissues for the first time, in a study led by investigators at Weill Cornell Medicine and the New York Genome Center.

Whole-genome sequencing may optimize PARP inhibitor use

The approach shows early promise over current commercial methods for identifying more patients likely to benefit from PARP inhibitor cancer treatments.